24/7 Emergency & General Advisory
🚨 24/7 Medical Emergency
Non-Emergency Advisory
10:00 AM – 6:00 PM, Mon–Sat
For appointments & general queries.
Join our healthcare community
Stay updated with our latest healthcare news and your appointments.
Prostate cancer has long been considered "immune cold," meaning it's unusually good at hiding from the immune system, which is part of why immunotherapy often doesn't work well against it. A new study from Duke University School of Medicine and the University of Rochester Medical Center used a CRISP
Immunotherapy has changed outcomes for a lot of cancers over the past decade. Prostate cancer has mostly sat outside that progress, and for a specific, frustrating reason: many prostate tumors are what researchers call "immune cold," meaning they barely attract the immune cells needed for immunotherapy to do anything at all. A new study offers a genuinely clever explanation for part of why that happens, and a possible way around it.
The research comes from a joint team at Duke University School of Medicine and the University of Rochester Medical Center, published in Nature Biomedical Engineering. It's animal research, done in mice, and worth understanding on those terms rather than as a finished treatment.
To understand what the researchers fixed, it helps to know what normally goes wrong. Cells display fragments of their internal proteins on their surface using a molecular structure called MHC-I, essentially a way of showing the immune system what's going on inside. T cells, the immune cells immunotherapy relies on, use MHC-I displays to recognize and target abnormal or cancerous cells.
In prostate cancer, the researchers found that a gene called SPSB1 gets involved in a way that suppresses MHC-I. The mRNA, the molecular messenger that carries instructions for building the SPSB1 protein, ends up shortened in prostate cancer cells. A shortened mRNA produces more SPSB1 protein, and more SPSB1 protein means less MHC-I on the cell surface. Less MHC-I means T cells have nothing to grab onto. No magnet, no attack. That's the practical meaning of a tumor being "immune cold," and it's a big part of why immunotherapy alone hasn't done much for prostate cancer specifically.
This is the part that makes the study interesting beyond prostate cancer specifically. Most people associate CRISPR with cutting DNA, but the tool used here works differently. The researchers used an RNA-targeting system based on CRISPR-Cas13, engineered to attach to a specific section of the SPSB1 mRNA rather than cut it.
By binding to that spot, the tool physically blocks cancer cells from shortening the mRNA's tail the way they normally would. The mRNA stays at its natural length, SPSB1 protein production drops back down, and MHC-I returns to the cell surface. Once that happened in the study's mouse models, prostate tumors became visible to the immune system again, and immune checkpoint therapy, a common form of immunotherapy, became significantly more effective against them.
In clinical practice, this is often the piece that's hardest to convey to patients asking about immunotherapy for prostate cancer: it isn't that the treatment doesn't work in general, it's that the tumor itself is often built to evade it. A tool that addresses that evasion mechanism directly, rather than just intensifying the immune attack, is a different kind of approach than most immunotherapy research has tried.
The researchers reported that restoring MHC-I expression through this method drew more T cells into the tumors and meaningfully improved how well immune checkpoint therapy worked against them. They also ran a detailed analysis specifically looking for off-target effects, meaning unintended changes elsewhere in the genome or transcriptome, and reported not detecting any in this study.
That off-target analysis matters more than it might seem. Gene-editing tools carry a real risk of affecting more than their intended target, and demonstrating a clean result, at least within the scope of what this study measured, is a meaningful part of building confidence in a technique like this one.
This needs to be said plainly, because the gap between an encouraging mouse study and something available to patients is genuinely large. This research hasn't been tested in humans. Mouse models are a standard and valuable step in cancer research, but plenty of approaches that work well in mice don't translate directly to people, whether due to differences in immune system behavior, dosing, delivery challenges, or effects that only show up over longer timeframes than a mouse study covers.
Current prostate cancer treatment still relies on established approaches: surgery, radiation, hormone therapy, and chemotherapy depending on the stage and specifics of the disease, with imaging tools like MRI playing a role in diagnosis and monitoring. Nothing about this study changes what a prostate cancer diagnosis means for treatment today.
Part of what makes this research notable is that immune-cold tumors aren't unique to prostate cancer. Several other hard-to-treat cancers share the same basic problem, poor T cell infiltration limiting how well immunotherapy can work. If the mechanism identified here, or something similar, turns out to apply more broadly, the implications could extend well past this one cancer type, though that's a genuinely open question rather than something this study answers.
Nothing about this study should change a current treatment plan, and there's no clinical trial or approved therapy stemming from it yet to ask about. What it does offer is a better understanding of one reason immunotherapy has struggled against this cancer specifically, and a promising, well-controlled early step toward addressing it. Genuine questions about treatment options, including immunotherapy eligibility, belong with a treating oncologist rather than a research headline.
Chemotherapy Explained: Understanding This Vital Cancer Treatment
Can an MRI Detect Cancer? Understanding Its Role in Diagnosis
Understanding Bone Cancer: Symptoms, Causes, and When to Seek Help
Visit Hospital
Near You
Find verified endocrinologists in Lucknow on DOCTAR. Compare experience, ratings, consultation fees and hospital locations, then book an appointment online.
August 22, 2026
Hormonal problems can affect weight, blood sugar, periods, energy levels, growth and several other parts of health. A hormone specialist, usually an endocrinologist, evaluates conditions involving the body's hormone-producing glands.
August 22, 2026
Find and book verified family doctors (general physicians) in Kolkata. Compare 327 doctors by fees (₹200–₹1,500), experience, ratings and hospital affiliation. Same-day appointments available with 316 doctors. Consultations in English, Hindi and Bengali.
August 22, 2026